Herpes simplex virus 1 (HSV-1) is a member of the herpesvirus family, Herpesviridae, that infect humans. HSV-1 (which produces most cold sores) is ubiquitous and contagious. As a neurotropic and neuroinvasive virus, HSV-1 persists in the body by becoming latent and hiding from the immune system in the cell bodies of neurons. HSV-1 has been reported to have a pathogenesis role in Herpes simplex encephalitis (HSE) and seropositivity to HSV-1 antibodies has been correlated with increased risk of Alzheimer's disease.
most frequent manifestation of sensory neuropathy
most frequent manifestation of sensory neuropathy
Anti-Hu Antibody (ANNA-1) – What Your Lab Result Means What is Anti-Hu? Anti-Hu antibodies (also called ANNA-1, or anti-neuronal nuclear antibody type 1) are a type of autoantibody—a protein made by your immune system that mistakenly attacks your own body’s cells. Specifically, Anti-Hu targets parts of the nervous system. Its presence in the blood may be a sign of an autoimmune neurological disorder often linked to certain types of cancer. Why Is This Marker Important? Anti-Hu antibodies are commonly associated with paraneoplastic neurologic syndromes (PNS)—a group of rare disorders that occur when the immune system reacts to a hidden (occult) tumor by attacking the nervous system. These antibodies are most often linked to small cell lung cancer, but may also be found in people with other cancers such as prostate, breast, or ovarian cancer. What a Positive Anti-Hu Result May Indicate: An autoimmune attack on the nervous system A potential underlying cancer (especially small cell lung cancer) Neurological symptoms such as: Memory loss Seizures Muscle weakness Numbness or tingling Difficulty walking or speaking What a Negative Result Means: A negative Anti-Hu result means this specific antibody was not found in your blood. However, it does not rule out other autoimmune or cancer-related causes of neurological symptoms. If symptoms persist, your doctor may recommend further testing with other paraneoplastic antibody panels. What to Do Next: If your Anti-Hu result is positive, your healthcare provider may order imaging studies (such as a CT scan or PET scan) and refer you to a neurologist or oncologist. Early detection and treatment of the underlying cause—whether it’s a tumor or an autoimmune disorder—can significantly improve outcomes. In Summary: A positive Anti-Hu antibody test may be an early warning sign of an autoimmune condition affecting the nervous system, often linked to cancer. It’s an important clue that can help guide further evaluation and diagnosis.
The "Anti-Hydroxytryptamine" marker is an important indicator used to assess the potential for neurological disorders. Hydroxytryptamine, more commonly known as serotonin, is a crucial neurotransmitter in the human brain, playing a pivotal role in regulating mood, sleep, and digestion, among other vital functions. When the immune system produces antibodies against serotonin, indicated by the "Anti-Hydroxytryptamine" marker, it can signify an abnormal immune response that might affect neurological health. The presence of these antibodies could potentially lead to a variety of neurological conditions, as serotonin's normal function is disrupted, affecting the brain's communication pathways. These autoantibodies are found mainly in autoimmune encephalitis.
measures specific antibodies in your blood that target Immunoglobulin E
a potential sign of heart damage
associated with polymyositis and may also be seen in patients with dermatomyositis
Anti-Jo-1 Ab (RDL), or Anti-Histidyl-tRNA Synthetase Antibody, is a pivotal serological marker extensively used in the diagnosis and management of autoimmune disorders, particularly Idiopathic Inflammatory Myopathies (IIM), including Polymyositis (PM) and Dermatomyositis (DM). This autoantibody targets the histidyl-tRNA synthetase enzyme, which is crucial in protein synthesis. The presence of Anti-Jo-1 Ab is considered a hallmark feature of the Anti-Synthetase Syndrome, a subtype of IIM characterized by a unique clinical triad: myositis, interstitial lung disease, and polyarthritis. Patients positive for Anti-Jo-1 Ab often exhibit more severe symptoms, with a pronounced pulmonary involvement and a higher risk of developing interstitial lung disease, which can be a major determinant of prognosis. The detection of this antibody aids in stratifying patients based on clinical phenotypes, guiding therapeutic decisions, and monitoring disease progression and response to therapy. Furthermore, Anti-Jo-1 Ab is not only significant for its diagnostic value but also for its role in understanding the pathogenesis of autoimmune myopathies. Studies suggest that individuals with this antibody may have a distinct immune response, contributing to the specific clinical manifestations observed in Anti-Synthetase Syndrome. Therefore, the assessment of Anti-Jo-1 Ab is not only a critical component in the clinical evaluation of patients suspected of having autoimmune myopathies but also offers valuable insights into the underlying immunological mechanisms driving these conditions.
The Anti-La (SS-B) Antibody test is an important diagnostic tool for autoimmune disorders. This test specifically detects antibodies against the La (or SS-B) antigen, which is another key protein target in certain autoimmune diseases. The presence of Anti-La (SS-B) antibodies is closely associated with Sjögren's syndrome, a condition characterized by dry eyes and mouth due to immune-mediated damage to moisture-secreting glands. These antibodies are also seen in patients with systemic lupus erythematosus (SLE), though less commonly than in Sjögren's syndrome. The detection of Anti-La (SS-B) antibodies is particularly significant in the diagnosis of Sjögren's syndrome, as they are one of the primary serological markers for the disease. In pregnant women with autoimmune conditions, these antibodies are relevant due to their potential association with complications in the fetus, such as neonatal lupus and congenital heart block, similar to Anti-Ro (SS-A) antibodies. However, as with other autoimmune antibody tests, the presence of Anti-La (SS-B) antibodies should be interpreted in the context of the patient's overall clinical symptoms and other laboratory findings, as they can sometimes be present in individuals without any autoimmune disease.
Anti-LGI1 (IgG + IgA) measures immune reactivity to LGI1 (leucine-rich glioma-inactivated protein), a protein involved in: • Neuronal signaling and communication • Synaptic function and plasticity • Regulation of cognitive processing and memory • Maintenance of healthy electrical activity in the brain LGI1 plays a key role in how nerve cells communicate and stabilize signaling. The presence of IgG + IgA antibodies suggests the immune system may be reacting to LGI1 or related neural structures, which may reflect neuroinflammation, synaptic stress, or autoimmune-mediated neurological signaling changes. This marker is part of a brain-immune activation screen and does not by itself diagnose autoimmune encephalitis or seizure disorders, but may offer early clues of immune involvement in neurological pathways. A mild elevation in Anti-LGI1 (IgG + IgA) suggests subtle immune recognition of a neural signaling protein. This may reflect early neuroimmune activation, inflammation, or stress affecting brain communication pathways. This result does not diagnose autoimmune encephalitis or neurological disease. What it may suggest • Early immune signaling in neuronal pathways • Mild synaptic or neuroinflammatory stress • Lifestyle-related inflammation or metabolic strain Supportive strategies • Optimize sleep, stress, and circadian rhythm • Anti-inflammatory nutrition and omega-3 intake • Regular exercise for brain oxygenation and signaling • Prioritize gut health and fiber intake • Maintain blood sugar stability • Consider antioxidant-rich foods and lifestyle supports Useful to monitor over time, especially if cognitive or mood-related symptoms are present.
Intestinal Permeability Panel
Intestinal Permeability Panel